Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Subscribe to Newsletter Newsletter   RSS Feeds RSS Feeds

Video Releases    |    Pricing Plans    |    Today's News    |    News By Category    |    News By Region    |    News By Date    |    Business Directory    |    Private Branding
All Press Releases for June 22, 2009 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version    Bookmark del.icio.us    Diggs



Knocking the Wind Out of Asthmatics: Help from Hippocrates
Asthma and allergy sufferers have an alternative to Singulair and Zicam - The ALCAT Test 
x-small text small text medium text large text


    WARSAW, POLAND, June 22, 2009 /24-7PressRelease/ -- Last week the FDA knocked the wind out of asthmatics by requesting the manufacturers of Singulair, a popular leukotriene blocking asthma and allergy drug, to upgrade their warning against psychotic side effects. Further respiratory distress was imposed on Zicam users when the FDA also last week announced warnings that the drug may cause a loss of smell.

What's an allergy sufferer to do?

The manufacturers of the ALCAT Test, a food intolerance test, suggest going back to Hippocrates' dictum, "Let thy food be thy medicine and thy medicine be thy food". Last week while the FDA was issuing warnings about allergy drugs in the United States, researchers from the University of Pavia (Italy), Polyclinic San Mateo, were reporting at the annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) held in Warsaw, Poland, that the ALCAT Test can accurately predict foods that cause GI problems and dermatological symptoms.

The researchers reported that 54% of patients with GI problems, and 86% of patients with chronic urticaria and dermatitis, experienced, "significant improvement" merely by avoiding foods indicated by the ALCAT Test. The only treatment was avoidance of specific foods that were shown through the test to cause inappropriate immune activation.

The ALCAT Test is a simple blood test that requires only a small quantity of blood. The results are specified to each individual, based upon their own unique biochemical and genetic makeup. The test is quickly becoming recognized as a way to safely and effectively avoid chronic inflammatory and allergy like problems, like asthma, perennial rhinitis and skin problems, but also metabolic disorders that interfere with weight loss, and other inflammatory conditions such as arthritis and migraine, without the use of drugs.

Hippocrates must be smiling.

About Cell Science Systems

Cell Science Systems (CSS) is a vertically integrated life sciences company and the worldwide market leader in food sensitivity testing as the manufacturer of the ALCAT Test. ALCAT identifies cellular reactions to over 300 foods and chemicals. These inflammatory reactions are linked to chronic health problems like obesity and diabetes, as well as skin, joint, and digestive disorders. Located in Deerfield Beach, Florida, CSS is a FDA-inspected and registered, cGMP medical device manufacturer and operates a CLIA-certified laboratory.

For more information, please call Daniel Lassman at (954) 426-2304 or visit http://www.ALCAT.com


---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #

Press Release Keywords:
Read more Press Releases from Daniel Lassman:
Other Press Release Headlines:

Press Release Service & Press Release Distribution News Supplied By 24-7PressRelease.com
Press Release Contact Information:
Daniel Lassman
Cell Science Systems

Brand Manager
852 South Military Trail
Deerfield Beach, Florida
United States 33442
Voice: 954-426-2304
Fax: 954-428-8676
E-Mail: Email us Here
Website: Visit Our Website
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release. We are unable to assist you with any information regarding this release. 24-7 Press Release disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.